Yongwei K. Su

Carson Cancer Stem Cell Vaccines R&D Center, Guangdong Key Laboratory Of Genome Instability And Human Disease Prevention
Shenzhen, 518055, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

AML1-ETO hijacks a distal enhancer of NAT10 to reprogram glutathione metabolism and sustain leukemia stem cell stemness.

AML1-ETO hijacks a distal enhancer of NAT10 to reprogram glutathione metabolism and sustain leukemia stem cell stemness.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 01, 2026

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.

Journal: Biochemical pharmacology
Published: April 18, 2026

Loss of cystathionine-β-synthase contributes to elevated OXPHOS, a vulnerability in Ara-C-resistant Myeloid Leukemia in Down syndrome.

Loss of cystathionine-β-synthase contributes to elevated OXPHOS, a vulnerability in Ara-C-resistant Myeloid Leukemia in Down syndrome.

Journal: Biochemical pharmacology
Published: January 19, 2026

Enhancing the Nucleoside Analog Response with Translational Therapeutic Approaches to Overcome Resistance.

Enhancing the Nucleoside Analog Response with Translational Therapeutic Approaches to Overcome Resistance.

Journal: Cells
Published: December 16, 2025

ROS-responsive multifunctional hyaluronic acid/gelatin based adhesive hydrogel encapsulating baicalin and cerium dioxide nanozymes accelerates infected diabetic wounds healing.

ROS-responsive multifunctional hyaluronic acid/gelatin based adhesive hydrogel encapsulating baicalin and cerium dioxide nanozymes accelerates infected diabetic wounds healing.

Journal: International journal of biological macromolecules
Published: July 18, 2025

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress.

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress.

Journal: Journal of experimental & clinical cancer research : CR
Published: October 17, 2024

Loss of SETD8 Impairs Mitochondrial Homeostasis to Suppress Leukemia Stem Cell Function in t(8;21) Acute Myeloid Leukemia.

Loss of SETD8 Impairs Mitochondrial Homeostasis to Suppress Leukemia Stem Cell Function in t(8;21) Acute Myeloid Leukemia.

Journal: Cancer research
Published: October 04, 2024

Development of a 50 kV hydrogen-helium mixed ion beam implanter.

Development of a 50 kV hydrogen-helium mixed ion beam implanter.

Journal: The Review of scientific instruments
Published: January 29, 2024

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.

Journal: Biochemical pharmacology
Published: September 29, 2023

The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia.

The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia.

Journal: Cancer research
Published: September 06, 2023

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.

Journal: Research square
Published: May 10, 2023

Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.

Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.

Journal: Biochemical pharmacology
Published: April 11, 2023
Showing 1-12 of 26

Last Updated: 09/26/2026